Analysis of whether Bestifan (Viliru) is a targeted drug and its applicable tumor types

Belzutifan (Belzutifan) is an oral small molecule targeted drug. Its mechanism of action mainly interferes with the growth and angiogenesis of tumor cells by inhibiting HIF-2α (hypoxia-inducible factor-2α). HIF-2α is highly expressed in the hypoxic microenvironment of various tumors, promoting tumor cell proliferation, angiogenesis and anti-apoptosis, thus becoming an important target for tumor treatment. The targeting effect of bestifan can specifically block this pathway, thereby reducing tumor progression and angiogenesis.

In terms of clinical application, besotivan is mainly used to treat VHL (Von Hipper- Lindau disease). related tumors, especially renal clear cell carcinoma (RCC) and VHL syndrome-related renal and neuroendocrine tumors. In these patients, the HIF-2α signaling pathway is abnormally active, and Bezutivan can effectively inhibit tumor proliferation and provide treatment options for patients with unresectable or recurrent tumors.

In addition to VHL related tumors, studies have also shown that bezotivan may have potential therapeutic effects on other HIF-2α overactivated solid tumors, such as certain lung cancers, brain hemangiomas, etc. However, these applications are still in the clinical trial stage and require further verification of efficacy and safety. Therefore, its main indications are still focused on VHL-related renal and neuroendocrine tumors.

When using bestivan, patients should conduct treatment management and safety monitoring under the guidance of a doctor. Since long-term inhibition ofHIF-2α may affect hematopoietic function and electrolyte balance, regular monitoring of blood routine, electrolytes, liver and kidney functions is required. At the same time, reasonable assessment of the patient's tumor type and target expression level can help achieve optimal efficacy and reduce potential risks.

Reference materials:https://www.drugs.com/